Abstract
People with multiple sclerosis (MS), a chronic neurologic disease, typically have a brain magnetic resonance imaging (MRI) scan annually to make sure the medication they are using is working well. Although with age and given treatment advances, these scans often do not show new MS activity, it is difficult to know when to advise a given person to stop this monitoring algorithm. In this study, leveraging analyses we have already completed, we generated personalized predictions about the utility of brain MRI at a given time point for individuals with MS. The longer-term goals are to 1) create an easily digestible visualization of the results, 2) evaluate how well the predictions work over time, 3) characterize and limit unintentional bias in the algorithm’s predictions or deployment, and 4) assess if having the personalized information available reduces unnecessary brain MRIs, thereby improving the value of health care for people with MS.
Competing Interest Statement
Dr. Sotirchos has received personal compensation for serving as a Consultant for Ad Scientiam. Dr. Sotirchos has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Sotirchos has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Sotirchos has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Sotirchos has received personal compensation for serving as an Ad Hoc Reviewer with National Institutes of Health. Dr. Mowry has received royalty payments from UpToDate. Dr. Mowry has received research support from Biogen and Genentech, editorial royalties from UpToDate, and consulting fees from BeCareLink, LLC. Dr. Peter Calabresi has received personal compensation as a consultant for Novartis. Dr. Peter Calabresi has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Calabresi has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. An immediate family member of Dr. Calabresi has received personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board for MyMD. Dr. Calabresi has received personal compensation for serving as an Editor, Associate Editor, or Editorial Advisory Board Member and as a Grant reviewer for Myelin Repair Foundation. Dr. Calabresi has received publishing royalties from a publication relating to health care. Dr. Calabresi has received personal compensation for serving as a Study Section Member with NIH. Dr. Calabresi has received personal compensation for serving as a Speaker for CME with NYAS. Dr. Calabresi has received personal compensation for serving as a Speaker with Academic CME. Dr. Calabresi has received personal compensation for consulting with Lilly and Project Efflux. The institution of Dr. Calabresi has received research support from Genentech. The institution of Dr. Sotirchos has received research support from National Institutes of Health. The institution of Dr. Sotirchos has received research support from National Multiple Sclerosis Society. The institution of Dr. Sotirchos has received research support from Sumaira Foundation. The institution of Dr. Sotirchos has received research support from Genentech.
Funding Statement
This study was partially funded by JHU internal research investments.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Johns Hopkins Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors, subject to IRB and data use agreements.
